Improving disease understanding and outcome prediction in nodal marginal zone lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This international observational cohort study aims to enhance the molecular classification of nodal marginal zone lymphoma (NMZL) by retrospectively collecting coded tumor biological material and health-related patient data from institutional biobanks and medical records. Patients diagnosed with NMZL since January 1, 2000, will be enrolled, and their data will be systematically recorded and analyzed to identify key clinical and biological features. The study will utilize a unique identification code for each patient to ensure data integrity and confidentiality. Follow-up data will also be collected to monitor disease progression and treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female adults 18 years or older
2. Diagnosis of NMZL on lymph node histology after Jan 1st, 2000
3. Availability of tumor material from lymph node (either frozen or FFPE) collected when the patient was treatment naïve
4. Availability of the baseline and follow-up annotations

Exclusion Criteria:

1\. Nodal spread of a clinically occult extranodal MZL (this must have been ruled out by carefully evaluating the extranodal tissues draining to the involved lymph nodes by imaging or endoscopy)

Where it's running

• University of Miami
  Miami, Florida, United States Recruiting
• Mayo Clinic
  Rochester, Minnesota, United States Recruiting
• Weill Cornell Medical
  New York, New York, United States Recruiting
• Ohio Health Riverside Methodist Hospital
  Columbus, Ohio, United States Recruiting
• Hospital Italiano de Buenos Aires
  Buenos Aires, Argentina Recruiting
• Hematology Center after Prof. Yeolyan
  Yerevan, Armenia Recruiting

Study contacts

• Study coordinator: IELSG - Study Coordination Office
• Email: ielsg@ior.usi.ch
• Phone: +41586667321

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nemtabrutinib plus rituximab for marginal zone lymphoma

  This phase 2 trial tests whether combining nemtabrutinib with rituximab can help people with marginal zone lymphoma.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07583810

• Epcoritamab for newly diagnosed marginal zone lymphoma

  This trial will test whether the antibody drug epcoritamab helps adults who are newly diagnosed with marginal zone lymphoma.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06796998

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Treatment using modified T cells for certain types of lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with certain types of lymphoma that haven't responded to other therapies.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT04223765

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.